PDCD1 and neoplasm: Combining RT with anti-CTLA-4 therapy (7–10), anti-PD-1 (11–13), or anti-PD-L1 therapy (14–16), with RT doses ranging from 2 to 20 Gy in single and fractionated regimens, has resulted in prolonged survival and reduced tumor growth in preclinical tumor models (17).